A randomized controlled trial of the safety and efficacy of a topical gentamicin-collagen sponge in diabetic patients with a mild foot ulcer infection

Ilker Uçkay, Benjamin Kressmann, Sébastien Di Tommaso, Marina Portela, Heba Alwan, Hubert Vuagnat, Sophie Maître, Christophe Paoli, Benjamin A Lipsky, Ilker Uçkay, Benjamin Kressmann, Sébastien Di Tommaso, Marina Portela, Heba Alwan, Hubert Vuagnat, Sophie Maître, Christophe Paoli, Benjamin A Lipsky

Abstract

Objectives: The initial phase of infection of a foot ulcer in a person with diabetes is often categorized as mild. Clinicians usually treat these infections with antimicrobial therapy, often applied topically. Some experts, however, believe that mild diabetic foot ulcer infections will usually heal with local wound care alone, without antimicrobial therapy or dressings.

Methods: To evaluate the potential benefit of treatment with a topical antibiotic, we performed a single-center, investigator-blinded pilot study, randomizing (1:1) adult patients with a mild diabetic foot ulcer infection to treatment with a gentamicin-collagen sponge with local care versus local care alone. Systemic antibiotic agents were prohibited.

Results: We enrolled a total of 22 patients, 11 in the gentamicin-collagen sponge arm and 11 in the control arm. Overall, at end of therapy, 20 (91%) patients were categorized as achieving clinical cure of infection, and 2 (9%) as significant improvement. At the final study visit, only 12 (56%) of all patients achieved microbiological eradication of all pathogens. There was no difference in either clinical or microbiological outcomes in those who did or did not receive the gentamicin-collagen sponge, which was very well tolerated.

Conclusion: The results of this pilot trial suggest that topical antibiotic therapy with gentamicin-collagen sponge, although very well tolerated, does not appear to improve outcomes in mild diabetic foot ulcer infection.

Keywords: Gentamicin–collagen sponge; adverse drug events; antimicrobial safety; mild diabetic foot infections; topical antimicrobial therapy; wound infection; wound outcome.

Conflict of interest statement

Declaration of conflicting interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Study flowchart (patients included and excluded).
Figure 2.
Figure 2.
Median wound scores over 7 weeks, stratified by study arm.

References

    1. Lebowitz D, Gariani K, Kressmann B, et al. Are antibiotic-resistant pathogens more common in subsequent episodes of diabetic foot infection? Int J Infect Dis 2017; 59: 61–64.
    1. Lipsky BA, Aragón-Sánchez J, Diggle M, et al. ; International Working Group on the Diabetic Foot. IWGDF guidance on the diagnosis and management of foot infections in persons with diabetes. Diabetes Metab Res Rev 2016; 32: 45–74.
    1. Chahine EB, Sucher AJ. Skin and soft tissue infections. PSAP 2015; 1: 1–27.
    1. Chu Y, Wang C, Zhang J, et al. Can we stop antibiotic therapy when signs and symptoms have resolved in diabetic foot infection patients? Int J Low Extrem Wounds 2015; 14: 277–283.
    1. Weledji EP, Fokam P. Treatment of the diabetic foot—to amputate or not? BMC Surg 2014; 14: 83.
    1. Landsman A, Blume PA, Jordan DA, Jr, et al. An open-label, three-arm pilot study of the safety and efficacy of topical Microcyn Rx wound care versus oral levofloxacin versus combined therapy for mild diabetic foot infections. J Am Podiatr Med Assoc 2011; 101: 484–496.
    1. Lipsky BA, Kuss M, Edmonds M, et al. Topical application of a gentamicin-collagen sponge combined with systemic antibiotic therapy for the treatment of diabetic foot infections of moderate severity: a randomized, controlled, multicenter clinical trial. J Am Podiatr Med Assoc 2012; 102: 223–232.
    1. Abbas M, Uçkay I, Lipsky BA. In diabetic foot infections antibiotics are to treat infection, not to heal wounds. Expert Opin Pharmacother 2015; 16: 821–832.
    1. Dumville JC, Lipsky BA, Hoey C, et al. Topical antimicrobial agents for treating foot ulcers in people with diabetes. Cochrane Database Syst Rev 2017; 6: CD011038.
    1. Pexiganan versus placebo control for the treatment of mild infections of diabetic foot ulcers (OneStep-2). Identifier: NCT01594762, (accessed 19 September 2017).

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir